Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.5%
    Check dated 2025-02-24T09:44:24.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version (v2.14.2) of the NLM-NCBI services and products, along with a notice about potential performance issues due to heavy traffic.
    Difference
    0.6%
    Check dated 2025-02-06T21:49:40.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-22T13:04:14.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.1%
    Check dated 2025-01-08T03:05:06.000Z thumbnail image
  9. Check
    100 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.0%
    Check dated 2024-12-17T13:50:18.000Z thumbnail image
  10. Check
    108 days ago
    Change Detected
    Summary
    The study MK-3475-671 has updated its contact details and study location information, replacing the previous version with new details and a recent publication reference from the Lancet regarding neoadjuvant pembrolizumab plus chemotherapy.
    Difference
    3%
    Check dated 2024-12-10T07:48:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.